Journal of Contemporary Brachytherapy最新文献

{"title":"Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer.","authors":"Chuanjun Yan,&nbsp;Xianliang Wang,&nbsp;Aiping Wen,&nbsp;Jingyue Luo,&nbsp;Siyu Zhang,&nbsp;Pei Wang,&nbsp;Jie Li","doi":"10.5114/jcb.2023.128894","DOIUrl":"https://doi.org/10.5114/jcb.2023.128894","url":null,"abstract":"<p><strong>Purpose: </strong>To compare inverse planning simulated annealing (IPSA) and hybrid inverse planning optimization (HIPO) using dosimetric and radiobiological models, and provide a basis for selecting the optimization method for cervical cancer.</p><p><strong>Material and methods: </strong>This was a retrospective study including 32 patients with radical cervical cancer. Brachytherapy treatment plans were re-optimized using IPSA, HIPO1 (with a locked uterine tube), and HIPO2 (with an unlocked uterine tube). Dosimetric data, including isodose lines, HR-CTV (D₁₀₀, V_150%, V_200%, HI, and CI), and (bladder, rectum, and intestines) D_1cc, D_2cc for organs at risk (OARs) were also collected. Additionally, TCP, NTCP, BED, and EUBED were calculated, and differences were analyzed using matched samples <i>t</i>-test and Friedman test.</p><p><strong>Results: </strong>Compared with IPSA and HIPO2, HIPO1 had better V_150% and V_200% (<i>p</i> < 0.05). Compared with IPSA and HIPO1, HIPO2 had better D₁₀₀ and CI (<i>p</i> < 0.05). The doses to the bladder D_1cc (4.72 ±0.33 Gy)/D_2cc (4.47 ±0.29 Gy) and rectum D_1cc (4.50 ±0.61 Gy)/D_2cc (4.11 ±0.63 Gy) were lower in HIPO2 than in IPSA and HIPO1. EUBEDs for HR-CTV were higher in HIPO1 and HIPO2 than in IPSA by 1.39-1.63%. However, TCPs were not remarkably different among the three plans (<i>p</i> > 0.05). Also, the NTCP for the bladder was lower in HIPO2 than in IPSA and HIPO1 by 13.04% and 16.67%, respectively.</p><p><strong>Conclusions: </strong>Although the dosimetric parameters of IPSA, HIPO1, and HIPO2 are comparable, HIPO2 provides better dose conformability and lower NTCP. Therefore, HIPO2 is recommended as an optimization algorithm in IC/ISBT for cervical cancer.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"212-219"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/e3/JCB-15-50904.PMC10324594.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial brachytherapy for internal mammary node in breast cancer: A case report.","authors":"Subhas Pandit,&nbsp;Simit Sapkota,&nbsp;Sundar Suwal,&nbsp;Abish Adhikari,&nbsp;Prakriti Karki,&nbsp;Anjani Kumar Jha","doi":"10.5114/jcb.2023.129016","DOIUrl":"https://doi.org/10.5114/jcb.2023.129016","url":null,"abstract":"<p><p>This case study reports the feasibility, safety, and efficacy of interstitial brachytherapy for internal mammary nodal recurrence in a 68-year-old woman with triple-negative breast cancer. The patient had previously undergone mastectomy followed by chemotherapy and radiotherapy. However, an internal mammary node was discovered during a routine follow-up a year later, which was confirmed as metastatic carcinoma by fine needle aspiration, with no other metastatic lesions. The patient underwent interstitial brachytherapy under ultrasound and computed tomography (CT) guidance, with a prescribed dose of 20 Gray in one fraction. Follow-up CT scan imaging over a 2-year period of treatment showed a complete resolution of internal mammary node. Therefore, brachytherapy may be considered a potential treatment option for cases of isolated internal mammary node recurrence in breast cancer.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"229-233"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/56/JCB-15-50941.PMC10324595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in receipt of adjuvant brachytherapy for endometrial cancer patients before and after affordable care act: The impact of Medicaid expansion.","authors":"Amy Le,&nbsp;Jordan A Holmes","doi":"10.5114/jcb.2023.127838","DOIUrl":"https://doi.org/10.5114/jcb.2023.127838","url":null,"abstract":"<p><strong>Purpose: </strong>For patients with high-intermediate risk (HIR) endometrial cancer, adjuvant radiation (RT) reduces the risk of recurrence, but many patients do not receive RT. Under the Affordable Care Act (ACA), most states expanded Medicaid coverage. Our hypothesis was patients would be more likely to receive indicated adjuvant RT in states that expanded Medicaid compared with patients in states that did not expand Medicaid.</p><p><strong>Material and methods: </strong>National Cancer Database (NCDB) was used to identify patients aged 40-64 years with HIR endometrial adenocarcinoma, stage IA and grade 3 or stage IB and grade 1 or 2, diagnosed from 2010-2018. We conducted a difference-in-differences (DID) cross-sectional retrospective analysis comparing receipt of adjuvant RT among patients residing in Medicaid expansion and non-expansion states before and after ACA implementation (January 2014).</p><p><strong>Results: </strong>Expansion states had higher rates of adjuvant RT prior to January 2014 compared with non-expansion states (49.21% vs. 36.46%), and the proportion of patients who received adjuvant RT increased over the study period across both Medicaid expansion and non-expansion states. After Medicaid expansion, the non-expansion states had a larger absolute increase in adjuvant radiation resulting in a non-significant change in the difference in adjuvant radiation rates compared with baseline (crude increase: 9.63% vs. 7.45%, adjusted DID: -2.68 [95% CI: -7.12-1.75], <i>p</i> = 0.236).</p><p><strong>Conclusions: </strong>Medicaid expansion is likely not the most significant factor affecting access or receipt of adjuvant RT for HIR endometrial cancer patients. Further study could help inform policy and efforts to ensure all patients have access to guideline-recommended RT.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"206-211"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/ae/JCB-15-50785.PMC10324593.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trans-rectal ultrasound-guided hybrid intra-cavitary and interstitial brachytherapy in carcinoma cervix: A feasibility study from a tertiary cancer center in India.","authors":"Harjot Kaur Bajwa,&nbsp;Rohith Singareddy,&nbsp;Anil Kumar Talluri,&nbsp;Heena Kauser,&nbsp;Devender Reddy Boja,&nbsp;G Srikanth,&nbsp;Alluri Krishnam Raju,&nbsp;Nvn Madhusudhana Sresty,&nbsp;Vyshnavi Mytri","doi":"10.5114/jcb.2023.127816","DOIUrl":"https://doi.org/10.5114/jcb.2023.127816","url":null,"abstract":"<p><strong>Purpose: </strong>To report the feasibility of performing hybrid intra-cavitary and interstitial (IC/IS) brachytherapy in patients with carcinoma cervix under trans-rectal ultrasound (TRUS) guidance.</p><p><strong>Material and methods: </strong>All patients who received an external beam radiotherapy (EBRT) dose of 50 Gy in 25 fractions with weekly chemotherapy, followed by a brachytherapy boost (21 Gy in 3 fractions) were prospectively included for analysis. IC/IS brachytherapy was performed using Fletcher style tandem and ovoid applicator with interstitial component under TRUS guidance. Parameters of implant quality analyzed included ability to insert tandem, ratio of needles loaded to the number of needles inserted, and incidence of uterine or organ at risk (OARs) perforation. Dosimetric parameters evaluated were dose to point A*, TRAK, D₉₀ high-risk clinical target volume (HR-CTV), and D_2cc to OARs (bladder, rectum, and sigmoid). Width and thickness of the target was compared between TRUS (TRUS_w and TRUS_t) and MRI (MRI_w and MRI_t).</p><p><strong>Results: </strong>Twenty carcinoma cervix patients treated with IC/IS brachytherapy were included for analysis. The mean HR-CTV volume was 36 cc. The median number of needles used were 6 (range, 2-10 needles). None of the patients had uterine perforation. Two patients had bowel and bladder perforation. The mean D₉₀ HR-CTV and D₉₈ HR-CTV were 87.3 Gy and 82 Gy EQD₂, respectively. The mean D_2cc to the bladder, rectum, and sigmoid were 80 Gy, 70 Gy, and 64 Gy EQD₂, respectively. The mean dose to point A* was 70.4 Gy EQD₂. The mean TRAK was 0.40. The mean TRUS_w (±SD) and MRI_w (±SD) were 4.58 cm (±0.44) and 4.49 cm (±0.50), respectively. The mean TRUS_t (±SD) and MRI_t (±SD) were 2.7 cm (±0.59) and 2.62 cm (±0.59), respectively. On statistical analysis, there was a significant correlation between TRUS_w and MRI_w (<i>r</i> = 0.93), and TRUS_t and MRI_t (<i>r</i> = 0.98).</p><p><strong>Conclusions: </strong>TRUS-guided IC/IS brachytherapy is feasible and provides adequate coverage of the target, with acceptable doses to OARs.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"198-205"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/ff/JCB-15-50779.PMC10324591.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial tumor volume as an important predictor for indication of intra-cavitary brachytherapy, intra-cavitary/interstitial brachytherapy, and multi-catheter sole interstitial brachytherapy in cervical cancer patients treated with chemoradiotherapy.","authors":"Tadashi Takenaka,&nbsp;Hideya Yamazaki,&nbsp;Gen Suzuki,&nbsp;Koji Masui,&nbsp;Daisuke Shimizu,&nbsp;Tadayuki Kotsuma,&nbsp;Eiichi Tanaka,&nbsp;Ken Yoshida,&nbsp;Kei Yamada","doi":"10.5114/jcb.2023.128895","DOIUrl":"https://doi.org/10.5114/jcb.2023.128895","url":null,"abstract":"<p><strong>Purpose: </strong>Advances in three-dimensional image-guided brachytherapy technique allow for using intra-cavitary and interstitial brachytherapy (ICIS-BT), and sole interstitial brachytherapy (ISBT) in addition to conventional intra-cavitary brachytherapy (ICBT). However, no consensus has been reached regarding the choice of these techniques. The aim of this study was to propose the size criteria for indication of interstitial techniques.</p><p><strong>Material and methods: </strong>We examined initial gross tumor volume (GTV) at presentation and at each brachytherapy session. Also, dose volume histogram parameters for each modality were compared in 112 patients with cervical cancer treated with brachytherapy (ICBT, 54; ICIS-BT, 11; and ISBT, 47).</p><p><strong>Results: </strong>The average GTV at diagnosis was 80.9 cm³ (range, 4.4-343.2 cm³), which shrank to 20.6 cm³ (25.5% of initial volume, range, 0.0-124.8 cm³) at initial brachytherapy. GTV > 30 cm³ at brachytherapy and high-risk clinical target volume > 40 cm³ were good threshold values for indication of interstitial technique, and tumors with initial GTV > 150 cm³ could be candidates for ISBT. An ISBT dose of 89.10 Gy can be prescribed in equivalent dose in 2 Gy fractions (range, 65.5-107.6 Gy), which was higher than those of ICIS (73.94 Gy, range, 71.44-82.50 Gy) and ICBT (72.83 Gy, range, 62.50-82.27 Gy) (<i>p</i> < 0.0001).</p><p><strong>Conclusions: </strong>Initial tumor volume is an important predictor for indication of ICBT and ICIS-BT. ISBT or at least an interstitial technique is recommended for initial GTV > 150 cm³.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 3","pages":"191-197"},"PeriodicalIF":1.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/10/JCB-15-50905.PMC10324585.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the bladder neck as an important organ at risk in prostate seed brachytherapy based on D_2cc: A single-institution, retrospective review.","authors":"Neil D Wallace,&nbsp;Karen L Olden,&nbsp;Victoria S Brennan,&nbsp;Mohd Mat Samuji,&nbsp;Muhammad Faisal Jamaluddin,&nbsp;Gerard McVey,&nbsp;Mary T Dunne,&nbsp;Paul J Kelly","doi":"10.5114/jcb.2023.126315","DOIUrl":"https://doi.org/10.5114/jcb.2023.126315","url":null,"abstract":"<p><strong>Purpose: </strong>International guidelines recommend urethral dose volume constraints to minimize the risk of urinary toxicity after prostate brachytherapy. An association between dose to the bladder neck (BN) and toxicity has previously been reported, and we sought to evaluate the impact of this organ at risk on urinary toxicity, based on intra-operative contouring.</p><p><strong>Material and methods: </strong>Rates of acute and late urinary toxicity (AUT and LUT, respectively) were graded according to CTCAE version 5.0 for 209 consecutive patients who underwent low-dose-rate (LDR) brachytherapy monotherapy, with approximately equal numbers treated before and after we began routinely contouring the BN. AUT and LUT were compared in patients treated before and after we began contouring the OAR, and also for those treated after we began contouring who had a D_2cc of greater than or less than 50% prescription dose.</p><p><strong>Results: </strong>AUT and LUT fell after intra-operative BN contouring was instituted. Rates of grade ≥ 2 AUT fell from 15/101 (15%) to 9/104 (8.6%), <i>p</i> = 0.245. Grade ≥ 2 LUT decreased from 32/100 (32%) to 18/100 (18%), <i>p</i> = 0.034. Grade ≥ 2 AUT was observed in 4/63 (6.3%) and 5/34 (15%) of those with a BN D_2cc >/≤ 50%, respectively, of prescription dose. Corresponding rates for LUT were 11/62 (18%) and 5/32 (16%).</p><p><strong>Conclusions: </strong>There were lower urinary toxicity rates for patients treated after we commenced routine intra-operative contouring of the BN. No clear relationship was observed between dosimetry and toxicity in our population.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 2","pages":"96-102"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/f9/JCB-15-50479.PMC10196733.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10153814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity.","authors":"Thirza Opbroek,&nbsp;Anne Cobussen,&nbsp;Evert J Van Limbergen,&nbsp;Ben G L Vanneste","doi":"10.5114/jcb.2023.126051","DOIUrl":"https://doi.org/10.5114/jcb.2023.126051","url":null,"abstract":"<p><strong>Purpose: </strong>Locally recurrent prostate cancer after previous radiation therapy remains challenging. One of the curative options for these patients is salvage brachytherapy. There are no reports available on the use of a biodegradable rectal balloon implantation (RBI) in combination with brachytherapy in patients with recurrent prostate cancer after previous radiotherapy.</p><p><strong>Case presentation: </strong>Here, we report on a patient with a local recurrence at five years after previous low-dose-rate brachytherapy with a prescribed dose of 145 Gray (Gy) for a low-risk prostate adenocarcinoma. The patient experienced grade 3 rectal toxicity, which was resolved at the time of local recurrence. He was treated with focal high-dose-rate (HDR) brachytherapy of 2 fr. × 13 Gy after RBI implantation. Four years post-salvage treatment, there was no evidence of biochemical recurrence according Phoenix definition, and no gastro-intestinal or genitourinary toxicity.</p><p><strong>Conclusions: </strong>This case describes the use of RBI implantation in combination with a focal salvage HDR in a patient with recurrent disease, with significant initial grade 3 rectal toxicity after previous irradiation. The use of a biodegradable RBI proved to be a promising solution for such a patient; however, this method needs to be further investigated.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 2","pages":"154-158"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/88/JCB-15-50391.PMC10196732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-operative interstitial brachytherapy in a novel infra-zygomatic approach for partially resectable head and neck cancers around the base of skull: A technical note.","authors":"Siddanna R Palled,&nbsp;Jaswanthi Akkpatti Ramachandra Reddy,&nbsp;Purushottam Chavan,&nbsp;K Siddappa,&nbsp;R A Sunil,&nbsp;Sanjeet Kumar Mondal,&nbsp;Bindu Krishnappa Venugopal,&nbsp;V Lokesh","doi":"10.5114/jcb.2023.126861","DOIUrl":"https://doi.org/10.5114/jcb.2023.126861","url":null,"abstract":"<p><strong>Purpose: </strong>To report an intra-operative catheter insertion technique into the base of skull tumor bed following surgical resection for maxillary tumors.</p><p><strong>Material and methods: </strong>A 42-year-old male patient diagnosed with carcinoma of the maxilla was treated with neoadjuvant chemotherapy followed by chemo-radiation using external beam technique combined with brachytherapy boost to post-operative bed. Brachytherapy was delivered <i>via</i> intra-operative catheter placement at the base of skull to residual disease, which was surgically unresectable. Initially, catheters were placed cranio-caudally. This was later changed into an infra-zygomatic approach to improve planning and dose coverage. High-risk clinical tumor volume (CTV) was generated with a 3 mm margin to residual gross tumor. Planning was done using Varian Eclipse brachytherapy planning system, and an optimal plan was generated.</p><p><strong>Conclusions: </strong>An innovative, beneficial, and safe brachytherapy approach is necessary in a difficult and critical area, such as the base of skull. Our novel method of implant insertion through infra-zygomatic approach resulted in a safe and successful procedure.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 2","pages":"148-153"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/1a/JCB-15-50579.PMC10196728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric comparison between microSelectron iridium-192 and flexi cobalt-60 sources in high-dose-rate brachytherapy using Geant4 Monte Carlo code.","authors":"Tsige Yhidego Gebremariam,&nbsp;Ghazale Geraily,&nbsp;Hussam Hameed Jassim,&nbsp;Somayeh Gholami","doi":"10.5114/jcb.2023.126238","DOIUrl":"https://doi.org/10.5114/jcb.2023.126238","url":null,"abstract":"<p><strong>Purpose: </strong>Manufacturing of miniaturized high activity iridium-192 (¹⁹²Ir) sources have been made a market preference in modern brachytherapy. Smaller dimensions of the sources are flexible for smaller diameter of the applicators, and it is also suitable for interstitial implants. Presently, cobalt-60 (⁶⁰Co) sources have been commercialized as an alternative to ¹⁹²Ir sources for high-dose-rate (HDR) brachytherapy, since ⁶⁰Co source have an advantage of longer half-life comparing with ¹⁹²Ir source. One of them is the HDR ⁶⁰Co Flexisource manufactured by Elekta. The purpose of this study was to compare the TG-43 dosimetric parameters of HDR flexi ⁶⁰Co and HDR microSelectron ¹⁹²Ir sources.</p><p><strong>Material and methods: </strong>Monte Carlo simulation code of Geant4 (v.11.0) was applied. Following the recommendations of AAPM TG-43 formalism report, Monte Carlo code of HDR flexi ⁶⁰Co and HDR microSelectron ¹⁹²Ir was validated by calculating radial dose function, anisotropy function, and dose-rate constants in a water phantom. Finally, results of both radionuclide sources were compared.</p><p><strong>Results: </strong>The calculated dose-rate constants per unit air-kerma strength in water medium were 1.108 cGy h^-1U^-1 for HDR microSelectron ¹⁹²Ir, and 1.097 cGy h^-1U^-1 for HDR flexi ⁶⁰Co source, with the percentage uncertainty of 1.1% and 0.2%, respectively. The values of radial dose function for distances above 22 cm for HDR flexi ⁶⁰Co source were higher than that of the other source. The anisotropic values sharply increased to the longitudinal sides of HDR flexi ⁶⁰Co source, and the rise was comparatively sharper to that of the other source.</p><p><strong>Conclusions: </strong>The primary photons from the lower-energy HDR microSelectron ¹⁹²Ir source have a limited range and are partially attenuated when considering the results of radial and anisotropic dose distribution functions. This implies that a HDR flexi ⁶⁰Co radionuclide could be used to treat tumors beyond the source compared with a HDR microSelectron ¹⁹²Ir source, despite the fact that ¹⁹²Ir has a lower exit dose than HDR flexi ⁶⁰Co radionuclide source.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 2","pages":"141-147"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/67/JCB-15-50437.PMC10196727.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9509134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study.","authors":"Danique A Scheltes,&nbsp;Elzbieta M van der Steen-Banasik,&nbsp;Geert A H J Smits","doi":"10.5114/jcb.2023.127050","DOIUrl":"https://doi.org/10.5114/jcb.2023.127050","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the quality of life (QoL) of patients with muscle-invasive bladder cancer (MIBC) who underwent bladder-sparing treatment with high-dose-rate brachytherapy, and compare their QoL with an age-matched general Dutch population.</p><p><strong>Material and methods: </strong>We conducted a single-center, prospective, descriptive cross-sectional study. MIBC patients who underwent brachytherapy-based bladder sparing treatment in Arnhem, The Netherlands from January 2016 to June 2021, were requested to complete the following questionnaires: European Organization for Research and Treatment of Cancer (EORTC) generic (QLQ-C30), bladder cancer-specific (QLQ-BLM30), and expanded prostate cancer index composite bowel (EPIC-50). Mean scores were calculated and compared with general Dutch population.</p><p><strong>Results: </strong>The mean global health status/QoL score of the treated patients was 80.6. High scores were noted in the functional scales, including physical (86.8), role (85.6), emotional (88.6), cognitive (88.3), and social functioning (88.9), while the main reported complains were related to fatigue (21.9) and urinary symptoms (25.1). Compared to the general Dutch population, significant differences were visible in global health status/QoL (80.6 vs. 75.7), pain (9.0 vs. 17.8), insomnia (23.3 vs. 15.2), and constipation (13.3 vs. 6.8). However, in no case did the mean score differ by more than ten points, which was considered clinically relevant.</p><p><strong>Conclusions: </strong>With a mean global health status/QoL score of 80.6, the patients after brachytherapy-based bladder sparing treatment have a good QoL. We found no clinically relevant difference in QoL comparing with an age-matched general Dutch population. The outcome strengthens the idea that this treatment option should be discussed with all patients eligible for brachytherapy-based treatment.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"15 2","pages":"110-116"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/3a/JCB-15-50617.PMC10196731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}